A study of 31 adults with obesity due to MC4R deficiency indicated that tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, may be a particularly effective therapeutic strategy [40]. Here, MC4R is linked to obesity disorder.